Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Convertible Debt (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Convertible Debt data on record, last reported at $198.3 million in Q3 2025.

  • For Q3 2025, Convertible Debt changed 0.49% year-over-year to $198.3 million; the TTM value through Sep 2025 reached $198.3 million, changed 0.49%, while the annual FY2024 figure was $197.5 million, 0.47% changed from the prior year.
  • Convertible Debt reached $198.3 million in Q3 2025 per GOSS's latest filing, roughly flat from $198.0 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $198.3 million in Q3 2025 and bottomed at $195.1 million in Q1 2022.
  • Average Convertible Debt over 4 years is $196.6 million, with a median of $196.6 million recorded in 2023.
  • Peak YoY movement for Convertible Debt: grew 0.43% in 2023, then grew 0.49% in 2025.
  • A 4-year view of Convertible Debt shows it stood at $195.7 million in 2022, then rose by 0.45% to $196.6 million in 2023, then rose by 0.47% to $197.5 million in 2024, then rose by 0.37% to $198.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $198.3 million in Q3 2025, $198.0 million in Q2 2025, and $197.8 million in Q1 2025.